BPC-157 Dosage Chart: Studied Doses, Reconstitution, Oral vs Subcutaneous

Key takeaways

• There is no established BPC-157 dose in humans. The entire published human record is three uncontrolled pilot studies from one clinic, and the only doses in them were an unreported intra-articular dose, 10 mg once into the bladder wall, and 10 to 20 mg by intravenous infusion.
• The seller chart of 250 to 500 mcg once or twice daily appears to be scaled from the rat dose of 10 mcg/kg, which converts to between about 110 and 700 mcg for a 70 kg adult depending on the method. A conversion is arithmetic, not a study.
• Seller reconstitution claims decode to tiny syringe volumes: with the usual 2 mL in a vial, their 250 mcg is 10 units from a 5 mg vial and 5 units from a 10 mg vial, which is exactly the range where 10-fold measuring errors happen. We publish no mixing table, because no pharmacy label exists to check one against.
• Oral BPC-157 is not absurd (the peptide survives stomach acid and worked in rat drinking water) but no human oral pharmacokinetic data exist, the one registered tablet study never reported results, and injected peptide is cleared within about 30 minutes in animals.
• As of October 2026, no US pharmacy may compound BPC-157: it came off FDA's Category 2 list in April 2026 and was recommended 8-6-1 by the advisory committee in July over FDA's objections, but no rule has been published. Every vial sold today is a research vial.

A BPC-157 dosage chart can honestly contain only two kinds of numbers: the doses used in studies, which are rat doses plus three one-clinic human pilots, and the doses sellers claim, which trace to forums. No human study has established a dose, route, frequency or duration for BPC-157, so every chart presenting 250 mcg as a protocol is presenting a guess. This page lays out both sets of numbers and labels each, as part of our tendon and joint healing evidence review; the sibling TB-500 dosage page does the same for the other half of the Wolverine stack, and the BPC-157 profile grades the full evidence.

The dosage chart from the studies

Notice what is missing: a single study of the dose, route and schedule people actually use. Nobody has ever given humans daily subcutaneous BPC-157 in a study and measured anything, and the human doses that do exist are 20 to 80 times larger than the seller dose, given once, as procedures.

Where the seller numbers come from

Almost certainly from the rat dose, by arithmetic. Scale 10 mcg/kg to a 70 kg adult by body weight and you get 700 mcg a day; scale it by body surface area, the way FDA guidance converts animal doses, and you get about 110 mcg. The 250 to 500 mcg range sits conveniently between the two. That conversion is ours and the hub's, shown to explain the number's origin, and it proves nothing: the rat data themselves are odd as dosing evidence, since the Zagreb studies report the same benefit across a million-fold dose range, from micrograms to picograms per kilogram, a pattern most drugs do not show (Staresinic 2003). A 2026 drug-development review is blunter: no validated formulation, no human pharmacokinetics by mouth or under the skin, no dosing rationale, fewer than 30 humans ever studied (Mateescu 2026). FDA's reviewers added in July 2026 that the products on the market vary in composition with no settled salt or free-base form (HPM 2026), so two vials following the same chart may not even contain the same substance.

Reconstitution: decoded, not instructed

We publish no mixing table for BPC-157, for the same reason as our BAC water for BPC-157 page: a mixing volume is only meaningful for a product with a pharmacy label stating the milligrams, the diluent and a prescribed dose, and no such BPC-157 product exists in the United States. What we can do is decode the claims so you can read them for what they are.

Seller charts most often say to add 2 mL of bacteriostatic water to the vial. By their own arithmetic, a 5 mg vial then holds 2.5 mg/mL, so their 250 mcg dose is 0.1 mL, which is 10 units on a U-100 insulin syringe; a 10 mg vial holds 5 mg/mL, making the same dose 0.05 mL, or 5 units. The division is the only checkable part of the chart, and it is also where the danger sits: a 5-unit dose is two and a half marks on a syringe, and FDA's 2024 alert on compounded semaglutide described patients told to draw 5 units who drew 50, a 10-fold overdose made with a labeled pharmacy product (FDA 2024). An unlabeled research vial adds the deeper uncertainty that the 5 or 10 mg on the label is itself unverified, so every downstream microgram inherits an unknown error. Our reconstitution calculator exists for prescribed products where a label can check the arithmetic; for BPC-157 there is no label, so there is nothing legitimate to calculate.

Oral versus subcutaneous: what is actually known

BPC-157 is unusual among peptides in that the oral route is not inherently implausible: it is stable in gastric juice, and in the rat ligament study it worked dissolved in drinking water at roughly 2 mcg a day as well as it did injected (Cerovecki 2010). That is the entire case for capsules. Against it: no human oral pharmacokinetic study has ever been published, the one registered Phase 1 of oral tablets vanished without results (NCT02637284), and nobody knows whether a swallowed dose reaches the human bloodstream at all. For a gut-wall target, local action is at least conceivable; for a tendon or joint, the peptide would have to get into the blood, which has been shown in no one.

Injection delivers the peptide to the blood, but the intact molecule is cleared within about 30 minutes in animals (Mateescu 2026), which makes once-daily dosing another convention resting on nothing. Neither route has a single controlled human outcome to its name, and the oral versus injection comparison walks through the details. Note also that capsules sold as supplements are not legally dietary supplements; they are the same unapproved drug in a different package.

The legal line under every chart

A dosage chart implies a product you could legitimately dose, and for BPC-157 there is none. It has never been approved in any country, has no USP monograph and is not on FDA's 503A bulks list, so no licensed US pharmacy may compound it. It came off FDA's Category 2 safety-risk list on April 15, 2026 only because its nomination was withdrawn, and the advisory committee's 8-6-1 vote on July 23, 2026 to recommend it came over the objection of FDA's own reviewers, who cited the absence of randomized trials, uncertain product identity and immunogenicity risk (HPM 2026). No proposed rule has appeared as of October 2026. The practical consequences, including why a telehealth prescription changes nothing, are covered in is BPC-157 legal, and the side effects page covers what to watch for if you are already injecting it and when to seek care.

Bottom line

The honest BPC-157 dosage chart has two columns: what studies used, which is rat doses plus three one-off human procedures at one clinic, and what sellers claim, which is a scaled rat dose rounded for commerce. Between them sits everything that was never done: no human dose-finding, no pharmacokinetics, no randomized trial, no legal product, no verified vial. Decode the charts if you meet them, but a chart is not evidence, and in October 2026 nothing about BPC-157 dosing is.

Frequently asked questions

+−What is the BPC-157 dosage chart?

The chart that circulates, 250 to 500 mcg injected once or twice daily, or 500 mcg capsules, is a seller convention, not a studied dose. No human study has established a dose, route, frequency or duration for BPC-157. The only doses ever published in people were procedures at one clinic: 10 mg injected once into the bladder wall in 12 women, and 10 mg then 20 mg by intravenous infusion in 2 adults. The knee-pain series did not report its dose.

+−How many mcg of BPC-157 should I take?

No study can answer that, because none has established a human dose. The 250 to 500 mcg range on seller sites appears to be scaled from the rat dose of 10 mcg/kg, which converts to roughly 700 mcg a day for a 70 kg adult by body weight or about 110 mcg by body surface area. A conversion is arithmetic, not evidence: it says nothing about whether any amount works, is safe or reaches a tendon in a person.

+−How do you reconstitute BPC-157?

There is no legitimate instruction, because no US pharmacy may compound BPC-157 in October 2026 and no pharmacy label exists to follow. Seller charts usually say to add 2 mL of bacteriostatic water to a 5 mg or 10 mg vial; decoded, that makes their 250 mcg claim 10 units or 5 units on an insulin syringe. We publish that arithmetic so you can read a chart, not follow one, and we publish no mixing table of our own.

+−Is oral BPC-157 as effective as the injection?

Nobody knows, because neither has been properly tested in humans. The peptide survives stomach acid and healed ligaments in rats when dissolved in drinking water, which is the basis for capsules; whether a swallowed dose reaches the human bloodstream has never been measured, and the one registered Phase 1 study of oral tablets never reported results. Injected, the intact peptide is cleared within about 30 minutes in animals. The comparison guide covers what little is known.

+−What dose of BPC-157 was used in human studies?

Three doses exist in the entire published human record, all from one Florida clinic: an unreported intra-articular dose in 16 knee-pain patients, a single 10 mg injection around the bladder wall in 12 women with interstitial cystitis, and intravenous infusions of 10 mg then 20 mg in 2 adults. None was a daily subcutaneous shot, none had a control group, and none resembles the 250 to 500 mcg seller schedule.

+−Why is there no official BPC-157 dose?

Because the work that produces one was never done: no human pharmacokinetic study by mouth or under the skin, no dose-finding trial, no randomized trial of any kind, as a 2026 drug-development review documents. FDA's reviewers made the same point in July 2026, noting the products on the market do not even have a settled form. The advisory committee's 8-6-1 vote to recommend it did not create a dose, and no pharmacy may compound it until FDA publishes a rule.

+−How long should you take BPC-157?

No study has defined a duration. The rat studies ran two to twelve weeks from a fresh surgical injury; the seller convention of 4 to 12 week cycles traces to forums, not data. There are no long-term human safety data at all, which is the stronger reason the question has no answer.

Sources

1. StudyStaresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 2003;21:976-83. (2003)
2. StudyCerovecki T et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res 2010;28:1155-61. (2010)
3. StudyLee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med 2021;27(4):8-13. (2021)
4. StudyLee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med 2024;30(10):12-17. (2024)
5. StudyLee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med 2025;31(5):20-24. (2025)
6. ReviewMateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics 2026;18:625. (2026)
7. SourceClinicalTrials.gov NCT02637284. Phase I pilot study in healthy volunteers to assess the safety and pharmacokinetics of PCO-02 (oral BPC-157 tablets): 42 participants planned, Mexico, 2015-2016; status unknown, no results posted. (2015)
8. RegulatoryFDA. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024. (2024)
9. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)